PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
32484272-5	2020	In agreement with these findings, most of the newly synthesized compounds demonstrated moderate to high sEH inhibitory activities, relative to 12-(3-adamantan-1-yl-ureido)dodecanoic acid as the reference standard.	12-(3-adamantan-1-ylureido)dodecanoic acid	143-186	epoxide hydrolase 2	Homo sapiens	104-107
31873869-4	2021	Most of the compounds showed moderate to high sEH inhibitory activities in in vitro test in comparison with 12-(3-Adamantan-1-yl-ureido)-dodecanoic acid, as a potent urea-based sEH inhibitor.	12-(3-adamantan-1-ylureido)dodecanoic acid	108-152	epoxide hydrolase 2	Homo sapiens	177-180
32903307-2	2020	In this study, we investigated the mechanism by which sEH inhibitor AUDA played an anti-inflammatory effect in HCAECs.	12-(3-adamantan-1-ylureido)dodecanoic acid	68-72	epoxide hydrolase 2	Homo sapiens	54-57
32903307-3	2020	Our results indicated that AUDA treatment promoted PPARgamma expression, while knockdown of PPARgamma blocked the cell growth and STAT1 expression inhibition induced by 100 mumol/L AUDA in HCAECs.	12-(3-adamantan-1-ylureido)dodecanoic acid	27-31	peroxisome proliferator activated receptor gamma	Homo sapiens	51-60
32903307-3	2020	Our results indicated that AUDA treatment promoted PPARgamma expression, while knockdown of PPARgamma blocked the cell growth and STAT1 expression inhibition induced by 100 mumol/L AUDA in HCAECs.	12-(3-adamantan-1-ylureido)dodecanoic acid	181-185	peroxisome proliferator activated receptor gamma	Homo sapiens	92-101
32903307-3	2020	Our results indicated that AUDA treatment promoted PPARgamma expression, while knockdown of PPARgamma blocked the cell growth and STAT1 expression inhibition induced by 100 mumol/L AUDA in HCAECs.	12-(3-adamantan-1-ylureido)dodecanoic acid	181-185	signal transducer and activator of transcription 1	Homo sapiens	130-135
32903307-11	2020	Our study indicated that AUDA played an anti-inflammatory effect in HCAECs through PPARgamma/STAT1 signaling pathway, and 14, 15-EET is up-regulated in children with KD, suggesting that 14, 15-EET involved in the progression of KD.	12-(3-adamantan-1-ylureido)dodecanoic acid	25-29	peroxisome proliferator activated receptor gamma	Homo sapiens	83-92
31866410-4	2020	AUDA, a sEH inhibitor, was given daily for 9 weeks orally, which significantly increased the level of 14,15-EET by inhibiting the expression of sEH and increasing the expression of CYP2J2 in lung tissues.	12-(3-adamantan-1-ylureido)dodecanoic acid	0-4	epoxide hydrolase 2, cytoplasmic	Mus musculus	8-11
31866410-4	2020	AUDA, a sEH inhibitor, was given daily for 9 weeks orally, which significantly increased the level of 14,15-EET by inhibiting the expression of sEH and increasing the expression of CYP2J2 in lung tissues.	12-(3-adamantan-1-ylureido)dodecanoic acid	0-4	epoxide hydrolase 2, cytoplasmic	Mus musculus	144-147
31866410-8	2020	The effect of AUDA on airway remodeling was related to the downregulation of extracellular-regulated protein kinases (Erk1/2), c-Jun N-terminal kinases (JNK) and signal transducer and activator of transcription 3 (STAT3).	12-(3-adamantan-1-ylureido)dodecanoic acid	14-18	mitogen-activated protein kinase 3	Mus musculus	118-124
31866410-8	2020	The effect of AUDA on airway remodeling was related to the downregulation of extracellular-regulated protein kinases (Erk1/2), c-Jun N-terminal kinases (JNK) and signal transducer and activator of transcription 3 (STAT3).	12-(3-adamantan-1-ylureido)dodecanoic acid	14-18	mitogen-activated protein kinase 8	Mus musculus	127-151
31866410-8	2020	The effect of AUDA on airway remodeling was related to the downregulation of extracellular-regulated protein kinases (Erk1/2), c-Jun N-terminal kinases (JNK) and signal transducer and activator of transcription 3 (STAT3).	12-(3-adamantan-1-ylureido)dodecanoic acid	14-18	mitogen-activated protein kinase 8	Mus musculus	153-156
31866410-8	2020	The effect of AUDA on airway remodeling was related to the downregulation of extracellular-regulated protein kinases (Erk1/2), c-Jun N-terminal kinases (JNK) and signal transducer and activator of transcription 3 (STAT3).	12-(3-adamantan-1-ylureido)dodecanoic acid	14-18	signal transducer and activator of transcription 3	Mus musculus	162-212
31866410-8	2020	The effect of AUDA on airway remodeling was related to the downregulation of extracellular-regulated protein kinases (Erk1/2), c-Jun N-terminal kinases (JNK) and signal transducer and activator of transcription 3 (STAT3).	12-(3-adamantan-1-ylureido)dodecanoic acid	14-18	signal transducer and activator of transcription 3	Mus musculus	214-219
31257558-6	2019	The anti-excitotoxic effects of 14,15-EET and AUDA were both blocked by the group 1 mGluR5 antagonist 2-methyl-6-(phenylethynyl)pyridine (MPEP), as were their protective effects against NMDA-disrupted perineuronal astrocyte processes expressing glutamate transporter-1 (GLT-1) and subsequent glutamate uptake.	12-(3-adamantan-1-ylureido)dodecanoic acid	46-50	glutamate receptor, ionotropic, kainate 1	Mus musculus	84-90
31257558-8	2019	The 14,15-EET/AUDA-preserved astroglial integrity was confirmed in glutamate-stimulated primary astrocytes along with the reduction of the c-Jun N-terminal kinase 1 phosphorylation, in which the 14,15-EET effect is mGluR5-dependent.	12-(3-adamantan-1-ylureido)dodecanoic acid	14-18	mitogen-activated protein kinase 8	Rattus norvegicus	139-164
31885501-4	2019	The objectives of this study were to (1) determine the localization of sEH and compare the changes it undergoes in the gestational tissues (placentas and fetal membranes) of women with normal-term pregnancies and those with pregnancies complicated by acute CAM; (2) study the effects of lipopolysaccharide (LPS) on the expression of sEH in the human gestational tissues; and (3) investigate the effect of 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), a specific sEH inhibitor, on LPS-induced changes in 14,15-DHET and cytokines such as interleukin- (IL-) 1beta and IL-6 in human gestational tissues in vitro and in pregnant mice.	12-(3-adamantan-1-ylureido)dodecanoic acid	405-449	epoxide hydrolase 2	Homo sapiens	71-74
31885501-4	2019	The objectives of this study were to (1) determine the localization of sEH and compare the changes it undergoes in the gestational tissues (placentas and fetal membranes) of women with normal-term pregnancies and those with pregnancies complicated by acute CAM; (2) study the effects of lipopolysaccharide (LPS) on the expression of sEH in the human gestational tissues; and (3) investigate the effect of 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), a specific sEH inhibitor, on LPS-induced changes in 14,15-DHET and cytokines such as interleukin- (IL-) 1beta and IL-6 in human gestational tissues in vitro and in pregnant mice.	12-(3-adamantan-1-ylureido)dodecanoic acid	451-455	epoxide hydrolase 2	Homo sapiens	71-74
31885501-6	2019	Furthermore, fetal membrane and villous explants treated with LPS had higher tissue levels of sEH mRNA and protein and 14,15-DHET than those present in the vehicle controls, while the administration of AUDA in the media attenuated the LPS-induced production of 14,15-DHET in tissue homogenates and IL-1beta and IL-6 in the media of explant cultures.	12-(3-adamantan-1-ylureido)dodecanoic acid	202-206	interleukin 1 beta	Homo sapiens	298-306
31885501-6	2019	Furthermore, fetal membrane and villous explants treated with LPS had higher tissue levels of sEH mRNA and protein and 14,15-DHET than those present in the vehicle controls, while the administration of AUDA in the media attenuated the LPS-induced production of 14,15-DHET in tissue homogenates and IL-1beta and IL-6 in the media of explant cultures.	12-(3-adamantan-1-ylureido)dodecanoic acid	202-206	interleukin 6	Homo sapiens	311-315
31885501-7	2019	Administration of AUDA also reduced the LPS-induced changes of 14,15-DHET, IL-1beta, and IL-6 in the placentas of pregnant mice.	12-(3-adamantan-1-ylureido)dodecanoic acid	18-22	interleukin 1 beta	Mus musculus	75-83
31885501-7	2019	Administration of AUDA also reduced the LPS-induced changes of 14,15-DHET, IL-1beta, and IL-6 in the placentas of pregnant mice.	12-(3-adamantan-1-ylureido)dodecanoic acid	18-22	interleukin 6	Mus musculus	89-93
31257558-8	2019	The 14,15-EET/AUDA-preserved astroglial integrity was confirmed in glutamate-stimulated primary astrocytes along with the reduction of the c-Jun N-terminal kinase 1 phosphorylation, in which the 14,15-EET effect is mGluR5-dependent.	12-(3-adamantan-1-ylureido)dodecanoic acid	14-18	glutamate receptor, ionotropic, kainate 1	Mus musculus	215-221
31257558-6	2019	The anti-excitotoxic effects of 14,15-EET and AUDA were both blocked by the group 1 mGluR5 antagonist 2-methyl-6-(phenylethynyl)pyridine (MPEP), as were their protective effects against NMDA-disrupted perineuronal astrocyte processes expressing glutamate transporter-1 (GLT-1) and subsequent glutamate uptake.	12-(3-adamantan-1-ylureido)dodecanoic acid	46-50	solute carrier family 1 member 2	Rattus norvegicus	245-268
31257558-6	2019	The anti-excitotoxic effects of 14,15-EET and AUDA were both blocked by the group 1 mGluR5 antagonist 2-methyl-6-(phenylethynyl)pyridine (MPEP), as were their protective effects against NMDA-disrupted perineuronal astrocyte processes expressing glutamate transporter-1 (GLT-1) and subsequent glutamate uptake.	12-(3-adamantan-1-ylureido)dodecanoic acid	46-50	solute carrier family 1 member 2	Rattus norvegicus	270-275
29311641-3	2018	We used a permanent middle cerebral artery occlusion (MCAO) model in adult wild-type mice with the sEH inhibitor 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA) post-treatment and in sEH knockout (sEH KO) mice.	12-(3-adamantan-1-ylureido)dodecanoic acid	113-156	epoxide hydrolase 2, cytoplasmic	Mus musculus	99-102
30950936-4	2019	This study aimed to evaluate whether a selective sEH inhibitor, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), can regulate monocyte/macrophage polarization and improve motor function in the rats with ischemic stroke induced by middle cerebral artery occlusion.	12-(3-adamantan-1-ylureido)dodecanoic acid	64-108	epoxide hydrolase 2	Rattus norvegicus	49-52
30950936-4	2019	This study aimed to evaluate whether a selective sEH inhibitor, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), can regulate monocyte/macrophage polarization and improve motor function in the rats with ischemic stroke induced by middle cerebral artery occlusion.	12-(3-adamantan-1-ylureido)dodecanoic acid	110-114	epoxide hydrolase 2	Rattus norvegicus	49-52
30988740-6	2019	The present study aimed to determine whether an increase in EET levels induced by treatment with the sEH inhibitor 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA) promotes vascular repair in human coronary arterial endothelial cells (HCAECs) and reduces inflammation in a mouse model of KD induced by Lactobacillus casei cell wall extract.	12-(3-adamantan-1-ylureido)dodecanoic acid	115-159	epoxide hydrolase 2	Homo sapiens	101-104
30988740-6	2019	The present study aimed to determine whether an increase in EET levels induced by treatment with the sEH inhibitor 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA) promotes vascular repair in human coronary arterial endothelial cells (HCAECs) and reduces inflammation in a mouse model of KD induced by Lactobacillus casei cell wall extract.	12-(3-adamantan-1-ylureido)dodecanoic acid	161-165	epoxide hydrolase 2	Homo sapiens	101-104
30988740-9	2019	Furthermore, in the mouse model of KD, AUDA reduced the protein expression of MMP-9, IL-1beta and TNF-alpha, indicating that AUDA may alleviate inflammatory reactions in the coronary arteries of KD model mice.	12-(3-adamantan-1-ylureido)dodecanoic acid	39-43	matrix metallopeptidase 9	Mus musculus	78-83
30988740-9	2019	Furthermore, in the mouse model of KD, AUDA reduced the protein expression of MMP-9, IL-1beta and TNF-alpha, indicating that AUDA may alleviate inflammatory reactions in the coronary arteries of KD model mice.	12-(3-adamantan-1-ylureido)dodecanoic acid	39-43	interleukin 1 beta	Mus musculus	85-93
30988740-9	2019	Furthermore, in the mouse model of KD, AUDA reduced the protein expression of MMP-9, IL-1beta and TNF-alpha, indicating that AUDA may alleviate inflammatory reactions in the coronary arteries of KD model mice.	12-(3-adamantan-1-ylureido)dodecanoic acid	39-43	tumor necrosis factor	Mus musculus	98-107
30988740-9	2019	Furthermore, in the mouse model of KD, AUDA reduced the protein expression of MMP-9, IL-1beta and TNF-alpha, indicating that AUDA may alleviate inflammatory reactions in the coronary arteries of KD model mice.	12-(3-adamantan-1-ylureido)dodecanoic acid	125-129	matrix metallopeptidase 9	Mus musculus	78-83
30988740-9	2019	Furthermore, in the mouse model of KD, AUDA reduced the protein expression of MMP-9, IL-1beta and TNF-alpha, indicating that AUDA may alleviate inflammatory reactions in the coronary arteries of KD model mice.	12-(3-adamantan-1-ylureido)dodecanoic acid	125-129	interleukin 1 beta	Mus musculus	85-93
30988740-9	2019	Furthermore, in the mouse model of KD, AUDA reduced the protein expression of MMP-9, IL-1beta and TNF-alpha, indicating that AUDA may alleviate inflammatory reactions in the coronary arteries of KD model mice.	12-(3-adamantan-1-ylureido)dodecanoic acid	125-129	tumor necrosis factor	Mus musculus	98-107
29574653-9	2018	Inhibition of sEH by an inhibitor, AUDA, dampened hyperoxia-induced ALI.	12-(3-adamantan-1-ylureido)dodecanoic acid	35-39	epoxide hydrolase 2, cytoplasmic	Mus musculus	14-17
29875688-15	2018	The cytochrome P450 epoxygenase inhibitor 17-octadecynoic acid (ODYA 10 muM) and the soluble epoxide hydrolase inhibitor 12-(3-adamantan-1-ylureido)-dodecanoic acid (AUDA 10 muM) slightly decreased PAME relaxations.	12-(3-adamantan-1-ylureido)dodecanoic acid	121-164	latexin	Homo sapiens	174-177
31686827-4	2019	This study aimed to investigate the effects of a selective sEH inhibitor, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), after ischemic stroke.	12-(3-adamantan-1-ylureido)dodecanoic acid	74-118	epoxide hydrolase 2	Rattus norvegicus	59-62
31686827-4	2019	This study aimed to investigate the effects of a selective sEH inhibitor, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), after ischemic stroke.	12-(3-adamantan-1-ylureido)dodecanoic acid	120-124	epoxide hydrolase 2	Rattus norvegicus	59-62
31686827-9	2019	Additionally, there was an increase in the mRNA expressions of antioxidant enzymes and anti-inflammatory interleukin-10, and pro-inflammatory mediators were decreased after AUDA administration.	12-(3-adamantan-1-ylureido)dodecanoic acid	173-177	interleukin 10	Rattus norvegicus	105-119
30725262-7	2019	Ischemia reperfusion experiments were repeated after administration of the sEH-inhibitor 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA).	12-(3-adamantan-1-ylureido)dodecanoic acid	89-132	epoxide hydrolase 2, cytoplasmic	Mus musculus	75-78
30725262-7	2019	Ischemia reperfusion experiments were repeated after administration of the sEH-inhibitor 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA).	12-(3-adamantan-1-ylureido)dodecanoic acid	134-138	epoxide hydrolase 2, cytoplasmic	Mus musculus	75-78
29311641-3	2018	We used a permanent middle cerebral artery occlusion (MCAO) model in adult wild-type mice with the sEH inhibitor 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA) post-treatment and in sEH knockout (sEH KO) mice.	12-(3-adamantan-1-ylureido)dodecanoic acid	158-162	epoxide hydrolase 2, cytoplasmic	Mus musculus	99-102
31966695-0	2017	Soluble epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid, represses human aortic smooth muscle cell proliferation and migration by regulating cell death pathways via the mTOR signaling.	12-(3-adamantan-1-ylureido)dodecanoic acid	37-81	mechanistic target of rapamycin kinase	Homo sapiens	195-199
29178914-5	2017	WT mice were injected intracerebroventricularly with 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), a selective sEH inhibitor, 30 min before ICH.	12-(3-adamantan-1-ylureido)dodecanoic acid	53-97	epoxide hydrolase 2, cytoplasmic	Mus musculus	118-121
29178914-5	2017	WT mice were injected intracerebroventricularly with 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), a selective sEH inhibitor, 30 min before ICH.	12-(3-adamantan-1-ylureido)dodecanoic acid	99-103	epoxide hydrolase 2, cytoplasmic	Mus musculus	118-121
28741242-5	2017	A potent sEH inhibitor 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA) was suspended in olive oil and administrated into animals in the intraperitoneal (i.p.)	12-(3-adamantan-1-ylureido)dodecanoic acid	23-67	epoxide hydrolase 2	Rattus norvegicus	9-12
28741242-5	2017	A potent sEH inhibitor 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA) was suspended in olive oil and administrated into animals in the intraperitoneal (i.p.)	12-(3-adamantan-1-ylureido)dodecanoic acid	69-73	epoxide hydrolase 2	Rattus norvegicus	9-12
29285425-3	2017	Results: sEH activity was inhibited by continuous release of the inhibitor 12-(3-adamantan-1-ylureido)-dodecanoic acid (AUDA) for 1 or 2 weeks.	12-(3-adamantan-1-ylureido)dodecanoic acid	75-118	epoxide hydrolase 2	Homo sapiens	9-12
29285425-3	2017	Results: sEH activity was inhibited by continuous release of the inhibitor 12-(3-adamantan-1-ylureido)-dodecanoic acid (AUDA) for 1 or 2 weeks.	12-(3-adamantan-1-ylureido)dodecanoic acid	120-124	epoxide hydrolase 2	Homo sapiens	9-12
29262558-3	2017	The effects of genetic deletion of sEH and treatment with an sEH inhibitor, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), on brain damage and inflammatory responses were evaluated in mice subjected to controlled cortical impact.	12-(3-adamantan-1-ylureido)dodecanoic acid	76-120	epoxide hydrolase 2, cytoplasmic	Mus musculus	61-64
29262558-10	2017	In primary microglial cultures, AUDA attenuated both LPS- or IFN-gamma-stimulated nitric oxide (NO) production and reduced LPS- or IFN-gamma-induced p38 MAPK and NF-kappaB signaling.	12-(3-adamantan-1-ylureido)dodecanoic acid	32-36	interferon gamma	Mus musculus	61-70
29262558-10	2017	In primary microglial cultures, AUDA attenuated both LPS- or IFN-gamma-stimulated nitric oxide (NO) production and reduced LPS- or IFN-gamma-induced p38 MAPK and NF-kappaB signaling.	12-(3-adamantan-1-ylureido)dodecanoic acid	32-36	interferon gamma	Mus musculus	131-140
29262558-10	2017	In primary microglial cultures, AUDA attenuated both LPS- or IFN-gamma-stimulated nitric oxide (NO) production and reduced LPS- or IFN-gamma-induced p38 MAPK and NF-kappaB signaling.	12-(3-adamantan-1-ylureido)dodecanoic acid	32-36	mitogen-activated protein kinase 14	Mus musculus	149-157
28694203-0	2017	Soluble epoxide hydrolase inhibitor AUDA decreases bleomycin-induced pulmonary toxicity in mice by inhibiting the p38/Smad3 pathways.	12-(3-adamantan-1-ylureido)dodecanoic acid	36-40	epoxide hydrolase 2, cytoplasmic	Mus musculus	0-25
28694203-0	2017	Soluble epoxide hydrolase inhibitor AUDA decreases bleomycin-induced pulmonary toxicity in mice by inhibiting the p38/Smad3 pathways.	12-(3-adamantan-1-ylureido)dodecanoic acid	36-40	mitogen-activated protein kinase 14	Mus musculus	114-117
28694203-0	2017	Soluble epoxide hydrolase inhibitor AUDA decreases bleomycin-induced pulmonary toxicity in mice by inhibiting the p38/Smad3 pathways.	12-(3-adamantan-1-ylureido)dodecanoic acid	36-40	SMAD family member 3	Mus musculus	118-123
31966695-2	2017	Scientific evidences indicate that sEH inhibitors such as 12-(3-Adamantan-1-yl-ureido)-dodecanoic acid (AUDA) could be a possible therapeutic option for cardiovascular diseases such as restenosis and atherosclerosis.	12-(3-adamantan-1-ylureido)dodecanoic acid	58-102	epoxide hydrolase 2	Homo sapiens	35-38
31966695-2	2017	Scientific evidences indicate that sEH inhibitors such as 12-(3-Adamantan-1-yl-ureido)-dodecanoic acid (AUDA) could be a possible therapeutic option for cardiovascular diseases such as restenosis and atherosclerosis.	12-(3-adamantan-1-ylureido)dodecanoic acid	104-108	epoxide hydrolase 2	Homo sapiens	35-38
31966695-4	2017	Herein, we intended to scrutinize the influence of AUDA on proliferation and migration of TNF-alpha-induced human aortic smooth muscle cells (HASMCs) and the underlying molecular mechanism.	12-(3-adamantan-1-ylureido)dodecanoic acid	51-55	tumor necrosis factor	Homo sapiens	90-99
31966695-5	2017	Pretreatment with AUDA (0.5-8 microM) dose-dependently inhibited TNF-alpha-induced proliferation of HASMCs as revealed by the MTT assay and the decreased expression of Cyclin D1 and beta-tubulin.	12-(3-adamantan-1-ylureido)dodecanoic acid	18-22	tumor necrosis factor	Homo sapiens	65-74
31966695-5	2017	Pretreatment with AUDA (0.5-8 microM) dose-dependently inhibited TNF-alpha-induced proliferation of HASMCs as revealed by the MTT assay and the decreased expression of Cyclin D1 and beta-tubulin.	12-(3-adamantan-1-ylureido)dodecanoic acid	18-22	cyclin D1	Homo sapiens	168-177
31966695-6	2017	Transwell analyses showed that AUDA equally suppressed TNF-alpha-induced migration of HASMCs.	12-(3-adamantan-1-ylureido)dodecanoic acid	31-35	tumor necrosis factor	Homo sapiens	55-64
31966695-7	2017	Moreover, AUDA induced the expression of apoptotic proteins (Caspase 3, PARP) and inhibited the expression of autophagy related markers (LC3-II and Beclin 1).	12-(3-adamantan-1-ylureido)dodecanoic acid	10-14	caspase 3	Homo sapiens	61-70
31966695-7	2017	Moreover, AUDA induced the expression of apoptotic proteins (Caspase 3, PARP) and inhibited the expression of autophagy related markers (LC3-II and Beclin 1).	12-(3-adamantan-1-ylureido)dodecanoic acid	10-14	collagen type XI alpha 2 chain	Homo sapiens	72-76
31966695-7	2017	Moreover, AUDA induced the expression of apoptotic proteins (Caspase 3, PARP) and inhibited the expression of autophagy related markers (LC3-II and Beclin 1).	12-(3-adamantan-1-ylureido)dodecanoic acid	10-14	beclin 1	Homo sapiens	137-156
31966695-8	2017	More interestingly, AUDA inhibited TNF-alpha-induced phosphorylation of mTOR, the silencing of which abolished the inhibitory effects of AUDA on TNF-alpha-induced HASMCs.	12-(3-adamantan-1-ylureido)dodecanoic acid	20-24	tumor necrosis factor	Homo sapiens	35-44
31966695-8	2017	More interestingly, AUDA inhibited TNF-alpha-induced phosphorylation of mTOR, the silencing of which abolished the inhibitory effects of AUDA on TNF-alpha-induced HASMCs.	12-(3-adamantan-1-ylureido)dodecanoic acid	20-24	mechanistic target of rapamycin kinase	Homo sapiens	72-76
31966695-8	2017	More interestingly, AUDA inhibited TNF-alpha-induced phosphorylation of mTOR, the silencing of which abolished the inhibitory effects of AUDA on TNF-alpha-induced HASMCs.	12-(3-adamantan-1-ylureido)dodecanoic acid	20-24	tumor necrosis factor	Homo sapiens	145-154
31966695-8	2017	More interestingly, AUDA inhibited TNF-alpha-induced phosphorylation of mTOR, the silencing of which abolished the inhibitory effects of AUDA on TNF-alpha-induced HASMCs.	12-(3-adamantan-1-ylureido)dodecanoic acid	137-141	tumor necrosis factor	Homo sapiens	35-44
31966695-8	2017	More interestingly, AUDA inhibited TNF-alpha-induced phosphorylation of mTOR, the silencing of which abolished the inhibitory effects of AUDA on TNF-alpha-induced HASMCs.	12-(3-adamantan-1-ylureido)dodecanoic acid	137-141	mechanistic target of rapamycin kinase	Homo sapiens	72-76
31966695-8	2017	More interestingly, AUDA inhibited TNF-alpha-induced phosphorylation of mTOR, the silencing of which abolished the inhibitory effects of AUDA on TNF-alpha-induced HASMCs.	12-(3-adamantan-1-ylureido)dodecanoic acid	137-141	tumor necrosis factor	Homo sapiens	145-154
31966695-9	2017	The present results point toward an inhibitory effect of AUDA on the proliferation and migration of TNF-alpha-induced HASMCs by regulation of cell death related signaling pathways via downregulation of the mTOR signaling.	12-(3-adamantan-1-ylureido)dodecanoic acid	57-61	tumor necrosis factor	Homo sapiens	100-109
31966695-9	2017	The present results point toward an inhibitory effect of AUDA on the proliferation and migration of TNF-alpha-induced HASMCs by regulation of cell death related signaling pathways via downregulation of the mTOR signaling.	12-(3-adamantan-1-ylureido)dodecanoic acid	57-61	mechanistic target of rapamycin kinase	Homo sapiens	206-210
27732913-9	2016	Maternal HF-induced programmed hypertension is associated with increased renal protein level of SEH and oxidative stress, which early AUDA therapy prevents.	12-(3-adamantan-1-ylureido)dodecanoic acid	134-138	epoxide hydrolase 2	Rattus norvegicus	96-99
28881620-4	2017	In addition, sEH inhibitor AUDA and 11,12-EET also decreased endothelial hyper-permeability in the in-vitro study.	12-(3-adamantan-1-ylureido)dodecanoic acid	27-31	epoxide hydrolase 2, cytoplasmic	Mus musculus	13-16
27210044-9	2016	The beneficial effects of AUDA and 15d-PGJ2 therapy include inhibition of SEH, increases of renal angiotensin converting enzyme-2 (ACE2) and angiotensin II type 2 receptor (AT2R) protein levels, and restoration of nitric oxide bioavailability.	12-(3-adamantan-1-ylureido)dodecanoic acid	26-30	epoxide hydrolase 2	Rattus norvegicus	74-77
27490848-3	2016	In this study, we determined whether a sEH inhibitor, AUDA, exerts lung protection in lipopolysaccharide (LPS)-induced ALI in mice.	12-(3-adamantan-1-ylureido)dodecanoic acid	54-58	epoxide hydrolase 2, cytoplasmic	Mus musculus	39-42
27490848-6	2016	RESULTS: AUDA administration decreased the pulmonary levels of monocyte chemoattractant protein (MCP)-1 and tumor necrosis factor (TNF)-alpha.	12-(3-adamantan-1-ylureido)dodecanoic acid	9-13	chemokine (C-C motif) ligand 2	Mus musculus	63-103
27490848-6	2016	RESULTS: AUDA administration decreased the pulmonary levels of monocyte chemoattractant protein (MCP)-1 and tumor necrosis factor (TNF)-alpha.	12-(3-adamantan-1-ylureido)dodecanoic acid	9-13	tumor necrosis factor	Mus musculus	108-141
27490848-8	2016	AUDA significantly inhibited sEH activity, and elevated epoxyeicosatrienoic acids (EETs) levels in lung tissues.	12-(3-adamantan-1-ylureido)dodecanoic acid	0-4	epoxide hydrolase 2, cytoplasmic	Mus musculus	29-32
27490848-9	2016	Moreover, LPS induced the activation of nuclear factor (NF)-kappaB was markedly dampened in AUDA treated group.	12-(3-adamantan-1-ylureido)dodecanoic acid	92-96	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	40-66
27210044-9	2016	The beneficial effects of AUDA and 15d-PGJ2 therapy include inhibition of SEH, increases of renal angiotensin converting enzyme-2 (ACE2) and angiotensin II type 2 receptor (AT2R) protein levels, and restoration of nitric oxide bioavailability.	12-(3-adamantan-1-ylureido)dodecanoic acid	26-30	angiotensin I converting enzyme 2	Rattus norvegicus	92-129
27210044-9	2016	The beneficial effects of AUDA and 15d-PGJ2 therapy include inhibition of SEH, increases of renal angiotensin converting enzyme-2 (ACE2) and angiotensin II type 2 receptor (AT2R) protein levels, and restoration of nitric oxide bioavailability.	12-(3-adamantan-1-ylureido)dodecanoic acid	26-30	angiotensin I converting enzyme 2	Rattus norvegicus	131-135
27210044-9	2016	The beneficial effects of AUDA and 15d-PGJ2 therapy include inhibition of SEH, increases of renal angiotensin converting enzyme-2 (ACE2) and angiotensin II type 2 receptor (AT2R) protein levels, and restoration of nitric oxide bioavailability.	12-(3-adamantan-1-ylureido)dodecanoic acid	26-30	angiotensin II receptor, type 2	Rattus norvegicus	141-171
27210044-9	2016	The beneficial effects of AUDA and 15d-PGJ2 therapy include inhibition of SEH, increases of renal angiotensin converting enzyme-2 (ACE2) and angiotensin II type 2 receptor (AT2R) protein levels, and restoration of nitric oxide bioavailability.	12-(3-adamantan-1-ylureido)dodecanoic acid	26-30	angiotensin II receptor, type 2	Rattus norvegicus	173-177
26494028-4	2015	This study aimed to test whether sEH C-terminal epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido) dodecanoic acid (AUDA) affects basal synaptic transmission and synaptic plasticity in the prefrontal cortex area (PFC).	12-(3-adamantan-1-ylureido)dodecanoic acid	77-121	epoxide hydrolase 2, cytoplasmic	Mus musculus	33-36
25663200-8	2016	Administration of sEH inhibitor AUDA significantly suppressed local inflammatory responses as indicated by the reduced microglia activation and IL-1 beta expression, as well as the decreased infiltration of neutrophils and T lymphocytes.	12-(3-adamantan-1-ylureido)dodecanoic acid	32-36	epoxide hydrolase 2	Rattus norvegicus	18-21
25663200-8	2016	Administration of sEH inhibitor AUDA significantly suppressed local inflammatory responses as indicated by the reduced microglia activation and IL-1 beta expression, as well as the decreased infiltration of neutrophils and T lymphocytes.	12-(3-adamantan-1-ylureido)dodecanoic acid	32-36	interleukin 1 beta	Rattus norvegicus	144-153
26494028-7	2015	Western Blotting demonstrated that AUDA treatment increased the expression of the N-methyl-D-aspartate receptor (NMDA) subunits NR1, NR2A, NR2B; the alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor subunits GluR1, GluR2, and ERK phosphorylation.	12-(3-adamantan-1-ylureido)dodecanoic acid	35-39	glutamate receptor, ionotropic, AMPA2 (alpha 2)	Mus musculus	238-243
26494028-4	2015	This study aimed to test whether sEH C-terminal epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido) dodecanoic acid (AUDA) affects basal synaptic transmission and synaptic plasticity in the prefrontal cortex area (PFC).	12-(3-adamantan-1-ylureido)dodecanoic acid	123-127	epoxide hydrolase 2, cytoplasmic	Mus musculus	33-36
26494028-7	2015	Western Blotting demonstrated that AUDA treatment increased the expression of the N-methyl-D-aspartate receptor (NMDA) subunits NR1, NR2A, NR2B; the alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor subunits GluR1, GluR2, and ERK phosphorylation.	12-(3-adamantan-1-ylureido)dodecanoic acid	35-39	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	128-131
26494028-7	2015	Western Blotting demonstrated that AUDA treatment increased the expression of the N-methyl-D-aspartate receptor (NMDA) subunits NR1, NR2A, NR2B; the alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor subunits GluR1, GluR2, and ERK phosphorylation.	12-(3-adamantan-1-ylureido)dodecanoic acid	35-39	glutamate receptor, ionotropic, NMDA2A (epsilon 1)	Mus musculus	133-137
26494028-7	2015	Western Blotting demonstrated that AUDA treatment increased the expression of the N-methyl-D-aspartate receptor (NMDA) subunits NR1, NR2A, NR2B; the alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor subunits GluR1, GluR2, and ERK phosphorylation.	12-(3-adamantan-1-ylureido)dodecanoic acid	35-39	glutamate receptor, ionotropic, NMDA2B (epsilon 2)	Mus musculus	139-143
26494028-7	2015	Western Blotting demonstrated that AUDA treatment increased the expression of the N-methyl-D-aspartate receptor (NMDA) subunits NR1, NR2A, NR2B; the alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor subunits GluR1, GluR2, and ERK phosphorylation.	12-(3-adamantan-1-ylureido)dodecanoic acid	35-39	glutamate receptor, ionotropic, AMPA1 (alpha 1)	Mus musculus	231-236
26086108-10	2015	The sEH inhibitors TPPU or AUDA inhibited LPS-induced NFkappaB activation and iNOS induction in mSMC, but had no effect on NFkappaB nuclear localization or inducible nitric oxide synthase in iSMC; effects which were recapitulated in part by addition of authentic epoxy-oxylipins.	12-(3-adamantan-1-ylureido)dodecanoic acid	27-31	epoxide hydrolase 2	Homo sapiens	4-7
25975094-1	2015	In this study, we aimed to detect the effects of the soluble epoxide hydrolase (sEH) inhibitor 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA) on atherosclerotic diseases and to explore its mechanism.	12-(3-adamantan-1-ylureido)dodecanoic acid	95-139	epoxide hydrolase 2, cytoplasmic	Mus musculus	53-78
25986738-7	2015	Importantly, pharmacological inhibition of sEH with 12-(3-adamantan-1-yl- ureido)-dodecanoic acid (AUDA) markedly suppressed PI3K-Akt activation and GSK-3beta phosphorylation.	12-(3-adamantan-1-ylureido)dodecanoic acid	52-97	epoxide hydrolase 2	Rattus norvegicus	43-46
25986738-7	2015	Importantly, pharmacological inhibition of sEH with 12-(3-adamantan-1-yl- ureido)-dodecanoic acid (AUDA) markedly suppressed PI3K-Akt activation and GSK-3beta phosphorylation.	12-(3-adamantan-1-ylureido)dodecanoic acid	52-97	AKT serine/threonine kinase 1	Rattus norvegicus	130-133
25986738-7	2015	Importantly, pharmacological inhibition of sEH with 12-(3-adamantan-1-yl- ureido)-dodecanoic acid (AUDA) markedly suppressed PI3K-Akt activation and GSK-3beta phosphorylation.	12-(3-adamantan-1-ylureido)dodecanoic acid	52-97	glycogen synthase kinase 3 beta	Rattus norvegicus	149-158
25986738-7	2015	Importantly, pharmacological inhibition of sEH with 12-(3-adamantan-1-yl- ureido)-dodecanoic acid (AUDA) markedly suppressed PI3K-Akt activation and GSK-3beta phosphorylation.	12-(3-adamantan-1-ylureido)dodecanoic acid	99-103	epoxide hydrolase 2	Rattus norvegicus	43-46
25986738-7	2015	Importantly, pharmacological inhibition of sEH with 12-(3-adamantan-1-yl- ureido)-dodecanoic acid (AUDA) markedly suppressed PI3K-Akt activation and GSK-3beta phosphorylation.	12-(3-adamantan-1-ylureido)dodecanoic acid	99-103	AKT serine/threonine kinase 1	Rattus norvegicus	130-133
25986738-7	2015	Importantly, pharmacological inhibition of sEH with 12-(3-adamantan-1-yl- ureido)-dodecanoic acid (AUDA) markedly suppressed PI3K-Akt activation and GSK-3beta phosphorylation.	12-(3-adamantan-1-ylureido)dodecanoic acid	99-103	glycogen synthase kinase 3 beta	Rattus norvegicus	149-158
25986738-8	2015	EMT associated E-cadherin suppression, alpha-SMA elevation and phenotypic transition were also attenuated by AUDA.	12-(3-adamantan-1-ylureido)dodecanoic acid	109-113	cadherin 1	Rattus norvegicus	15-25
25986738-8	2015	EMT associated E-cadherin suppression, alpha-SMA elevation and phenotypic transition were also attenuated by AUDA.	12-(3-adamantan-1-ylureido)dodecanoic acid	109-113	actin gamma 2, smooth muscle	Rattus norvegicus	39-48
25986738-9	2015	Furthermore, in rats with chronic proteinuric renal disease, AUDA treatment inhibited PI3K-Akt activation and GSK-3beta phosphorylation, while attenuating levels of EMT markers.	12-(3-adamantan-1-ylureido)dodecanoic acid	61-65	AKT serine/threonine kinase 1	Rattus norvegicus	91-94
25986738-9	2015	Furthermore, in rats with chronic proteinuric renal disease, AUDA treatment inhibited PI3K-Akt activation and GSK-3beta phosphorylation, while attenuating levels of EMT markers.	12-(3-adamantan-1-ylureido)dodecanoic acid	61-65	glycogen synthase kinase 3 beta	Rattus norvegicus	110-119
25366463-6	2015	In vivo experiments, we use 12-(3-adamantan-1-yl-ureido)-dodecanoic acid [AUDA, a specific soluble epoxide hydrolase (sEH) inhibitor] to confirm the effect of EETs indirectly.	12-(3-adamantan-1-ylureido)dodecanoic acid	74-78	epoxide hydrolase 2	Rattus norvegicus	118-121
25975094-1	2015	In this study, we aimed to detect the effects of the soluble epoxide hydrolase (sEH) inhibitor 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA) on atherosclerotic diseases and to explore its mechanism.	12-(3-adamantan-1-ylureido)dodecanoic acid	95-139	epoxide hydrolase 2, cytoplasmic	Mus musculus	80-83
25975094-1	2015	In this study, we aimed to detect the effects of the soluble epoxide hydrolase (sEH) inhibitor 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA) on atherosclerotic diseases and to explore its mechanism.	12-(3-adamantan-1-ylureido)dodecanoic acid	141-145	epoxide hydrolase 2, cytoplasmic	Mus musculus	53-78
25975094-1	2015	In this study, we aimed to detect the effects of the soluble epoxide hydrolase (sEH) inhibitor 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA) on atherosclerotic diseases and to explore its mechanism.	12-(3-adamantan-1-ylureido)dodecanoic acid	141-145	epoxide hydrolase 2, cytoplasmic	Mus musculus	80-83
21451419-7	2011	The sEH inhibitor 12-(3-adamantan-1-yl-ureido)dodecanoic acid administered for 2 weeks starting 5 weeks after surgery in 2K1C mice (25 mg/l in drinking water) reduced aortic pressures and cardiac hypertrophy, improved the coronary relaxations to acetylcholine and restored the inhibitory effect of fluconazole and MSPPOH on acetylcholine-induced relaxations, without modifying the relaxations to NS309 and NS1619.	12-(3-adamantan-1-ylureido)dodecanoic acid	18-61	epoxide hydrolase 2, cytoplasmic	Mus musculus	4-7
24631907-6	2014	In contrast, inhibition of soluble epoxide hydrolase by AUDA or TPPU inhibited basal, LPS, IL-1beta and PMA induced TNFalpha release, and LPS-induced NFkappaB p65 nuclear translocation.	12-(3-adamantan-1-ylureido)dodecanoic acid	56-60	RELA proto-oncogene, NF-kB subunit	Homo sapiens	159-162
24711829-5	2014	Most of the synthesized compounds have appropriate physical properties and exhibited considerable in-vitro sEH inhibitory activity in comparison with 12-(3-Adamantan-1-yl-ureido)- dodecanoicacid (AUDA), a potent urea-based sEH inhibitor.	12-(3-adamantan-1-ylureido)dodecanoic acid	150-194	epoxide hydrolase 2	Homo sapiens	223-226
22863680-6	2012	Furthermore, pre-treatment of the co-cultured cells with 12-(3-adamantan-1-yl-ureido)-dodecanoic acid, an inhibitor of the EET metabolizing enzyme, soluble epoxide hydrolase (sEH), before H(2)O(2) stimulation (1mM, for 1h) increased cell viability.	12-(3-adamantan-1-ylureido)dodecanoic acid	57-101	epoxide hydrolase 2	Homo sapiens	148-173
22863680-6	2012	Furthermore, pre-treatment of the co-cultured cells with 12-(3-adamantan-1-yl-ureido)-dodecanoic acid, an inhibitor of the EET metabolizing enzyme, soluble epoxide hydrolase (sEH), before H(2)O(2) stimulation (1mM, for 1h) increased cell viability.	12-(3-adamantan-1-ylureido)dodecanoic acid	57-101	epoxide hydrolase 2	Homo sapiens	175-178
22798687-6	2012	It is inhibited by a subclass of N,N"-disubstituted urea derivatives, including 12-(3-adamantan-1-yl-ureido)-dodecanoic acid, 1-cyclohexyl-3-dodecylurea, and 1-(1-acetylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea, compounds so far believed to be selective inhibitors of mammalian soluble epoxide hydrolase (sEH).	12-(3-adamantan-1-ylureido)dodecanoic acid	80-124	epoxide hydrolase 2	Homo sapiens	287-312
22798687-6	2012	It is inhibited by a subclass of N,N"-disubstituted urea derivatives, including 12-(3-adamantan-1-yl-ureido)-dodecanoic acid, 1-cyclohexyl-3-dodecylurea, and 1-(1-acetylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea, compounds so far believed to be selective inhibitors of mammalian soluble epoxide hydrolase (sEH).	12-(3-adamantan-1-ylureido)dodecanoic acid	80-124	epoxide hydrolase 2	Homo sapiens	314-317
21821146-7	2011	Interestingly, a significant and consistent synergic effect was observed when indomethacin and AUDA were simultaneously added, raising the possibility of a combined clinical use of cyclooxygenase and sEH inhibitors in attempt to treat preterm labor.	12-(3-adamantan-1-ylureido)dodecanoic acid	95-99	epoxide hydrolase 2	Homo sapiens	200-203
24631907-6	2014	In contrast, inhibition of soluble epoxide hydrolase by AUDA or TPPU inhibited basal, LPS, IL-1beta and PMA induced TNFalpha release, and LPS-induced NFkappaB p65 nuclear translocation.	12-(3-adamantan-1-ylureido)dodecanoic acid	56-60	epoxide hydrolase 2	Homo sapiens	27-52
24631907-6	2014	In contrast, inhibition of soluble epoxide hydrolase by AUDA or TPPU inhibited basal, LPS, IL-1beta and PMA induced TNFalpha release, and LPS-induced NFkappaB p65 nuclear translocation.	12-(3-adamantan-1-ylureido)dodecanoic acid	56-60	interleukin 1 beta	Homo sapiens	91-99
24631907-6	2014	In contrast, inhibition of soluble epoxide hydrolase by AUDA or TPPU inhibited basal, LPS, IL-1beta and PMA induced TNFalpha release, and LPS-induced NFkappaB p65 nuclear translocation.	12-(3-adamantan-1-ylureido)dodecanoic acid	56-60	tumor necrosis factor	Homo sapiens	116-124
22590647-3	2012	In this study, we therefore induced ischemia-reperfusion injury (IRI) in C57BL/6 mice and controlled sEH activity by intraperitoneal administration of the sEH inhibitor 12-(3-adamantan-1-ylureido)-dodecanoic acid (AUDA).	12-(3-adamantan-1-ylureido)dodecanoic acid	169-212	epoxide hydrolase 2, cytoplasmic	Mus musculus	101-104
22590647-3	2012	In this study, we therefore induced ischemia-reperfusion injury (IRI) in C57BL/6 mice and controlled sEH activity by intraperitoneal administration of the sEH inhibitor 12-(3-adamantan-1-ylureido)-dodecanoic acid (AUDA).	12-(3-adamantan-1-ylureido)dodecanoic acid	169-212	epoxide hydrolase 2, cytoplasmic	Mus musculus	155-158
22590647-3	2012	In this study, we therefore induced ischemia-reperfusion injury (IRI) in C57BL/6 mice and controlled sEH activity by intraperitoneal administration of the sEH inhibitor 12-(3-adamantan-1-ylureido)-dodecanoic acid (AUDA).	12-(3-adamantan-1-ylureido)dodecanoic acid	214-218	epoxide hydrolase 2, cytoplasmic	Mus musculus	155-158
22590647-8	2012	Ischemic injury had no effects on the plasma concentrations of EpOME and DHOME, but inhibition of sEH by AUDA significantly increased plasma EpOME and the EpOME/DHOME ratio.	12-(3-adamantan-1-ylureido)dodecanoic acid	105-109	epoxide hydrolase 2, cytoplasmic	Mus musculus	98-101
23008693-6	2011	The levels of EGFR, ERK, and PI3 kinase/AKT proteins were significantly induced by treatment of 14, 15-EET and 14,15-EET/AUDA, but no significant changes were observed by addition of GW9662.	12-(3-adamantan-1-ylureido)dodecanoic acid	121-125	epidermal growth factor receptor	Homo sapiens	14-18
21266668-1	2011	We hypothesized that perinatal inhibition of soluble epoxide hydrolase (SEH), which metabolizes epoxyeicosatrienoic acids in the arachidonic acid (AA) cascade, with an orally active SEH inhibitor, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), would persistently reduce blood pressure (BP) in adult SHR despite discontinuation of AUDA at 4 wk of age.	12-(3-adamantan-1-ylureido)dodecanoic acid	197-241	epoxide hydrolase 2	Rattus norvegicus	45-70
21266668-1	2011	We hypothesized that perinatal inhibition of soluble epoxide hydrolase (SEH), which metabolizes epoxyeicosatrienoic acids in the arachidonic acid (AA) cascade, with an orally active SEH inhibitor, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), would persistently reduce blood pressure (BP) in adult SHR despite discontinuation of AUDA at 4 wk of age.	12-(3-adamantan-1-ylureido)dodecanoic acid	197-241	epoxide hydrolase 2	Rattus norvegicus	72-75
21266668-1	2011	We hypothesized that perinatal inhibition of soluble epoxide hydrolase (SEH), which metabolizes epoxyeicosatrienoic acids in the arachidonic acid (AA) cascade, with an orally active SEH inhibitor, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), would persistently reduce blood pressure (BP) in adult SHR despite discontinuation of AUDA at 4 wk of age.	12-(3-adamantan-1-ylureido)dodecanoic acid	197-241	epoxide hydrolase 2	Rattus norvegicus	182-185
21266668-1	2011	We hypothesized that perinatal inhibition of soluble epoxide hydrolase (SEH), which metabolizes epoxyeicosatrienoic acids in the arachidonic acid (AA) cascade, with an orally active SEH inhibitor, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), would persistently reduce blood pressure (BP) in adult SHR despite discontinuation of AUDA at 4 wk of age.	12-(3-adamantan-1-ylureido)dodecanoic acid	243-247	epoxide hydrolase 2	Rattus norvegicus	45-70
21266668-1	2011	We hypothesized that perinatal inhibition of soluble epoxide hydrolase (SEH), which metabolizes epoxyeicosatrienoic acids in the arachidonic acid (AA) cascade, with an orally active SEH inhibitor, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), would persistently reduce blood pressure (BP) in adult SHR despite discontinuation of AUDA at 4 wk of age.	12-(3-adamantan-1-ylureido)dodecanoic acid	243-247	epoxide hydrolase 2	Rattus norvegicus	72-75
21266668-1	2011	We hypothesized that perinatal inhibition of soluble epoxide hydrolase (SEH), which metabolizes epoxyeicosatrienoic acids in the arachidonic acid (AA) cascade, with an orally active SEH inhibitor, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), would persistently reduce blood pressure (BP) in adult SHR despite discontinuation of AUDA at 4 wk of age.	12-(3-adamantan-1-ylureido)dodecanoic acid	243-247	epoxide hydrolase 2	Rattus norvegicus	182-185
21266668-1	2011	We hypothesized that perinatal inhibition of soluble epoxide hydrolase (SEH), which metabolizes epoxyeicosatrienoic acids in the arachidonic acid (AA) cascade, with an orally active SEH inhibitor, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), would persistently reduce blood pressure (BP) in adult SHR despite discontinuation of AUDA at 4 wk of age.	12-(3-adamantan-1-ylureido)dodecanoic acid	336-340	epoxide hydrolase 2	Rattus norvegicus	45-70
21266668-1	2011	We hypothesized that perinatal inhibition of soluble epoxide hydrolase (SEH), which metabolizes epoxyeicosatrienoic acids in the arachidonic acid (AA) cascade, with an orally active SEH inhibitor, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), would persistently reduce blood pressure (BP) in adult SHR despite discontinuation of AUDA at 4 wk of age.	12-(3-adamantan-1-ylureido)dodecanoic acid	336-340	epoxide hydrolase 2	Rattus norvegicus	72-75
21266668-1	2011	We hypothesized that perinatal inhibition of soluble epoxide hydrolase (SEH), which metabolizes epoxyeicosatrienoic acids in the arachidonic acid (AA) cascade, with an orally active SEH inhibitor, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), would persistently reduce blood pressure (BP) in adult SHR despite discontinuation of AUDA at 4 wk of age.	12-(3-adamantan-1-ylureido)dodecanoic acid	336-340	epoxide hydrolase 2	Rattus norvegicus	182-185
23008693-6	2011	The levels of EGFR, ERK, and PI3 kinase/AKT proteins were significantly induced by treatment of 14, 15-EET and 14,15-EET/AUDA, but no significant changes were observed by addition of GW9662.	12-(3-adamantan-1-ylureido)dodecanoic acid	121-125	mitogen-activated protein kinase 1	Homo sapiens	20-23
23008693-6	2011	The levels of EGFR, ERK, and PI3 kinase/AKT proteins were significantly induced by treatment of 14, 15-EET and 14,15-EET/AUDA, but no significant changes were observed by addition of GW9662.	12-(3-adamantan-1-ylureido)dodecanoic acid	121-125	AKT serine/threonine kinase 1	Homo sapiens	40-43
20224052-4	2010	METHODS AND RESULTS: Inhibition of sEH by 12-(3-adamantan-1-yl-ureido) dodecanoic acid or knockout of the enzyme significantly increased plasma EET levels.	12-(3-adamantan-1-ylureido)dodecanoic acid	42-86	epoxide hydrolase 2, cytoplasmic	Mus musculus	35-38
20008283-2	2010	Tension measurements performed in the presence of 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), a soluble epoxide hydrolase (sEH)-specific inhibitor, demonstrated that 17,18-EpETE reduced the reactivity of TNF-alpha-pretreated tissues.	12-(3-adamantan-1-ylureido)dodecanoic acid	50-94	epoxide hydrolase 2	Homo sapiens	105-130
20008283-2	2010	Tension measurements performed in the presence of 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), a soluble epoxide hydrolase (sEH)-specific inhibitor, demonstrated that 17,18-EpETE reduced the reactivity of TNF-alpha-pretreated tissues.	12-(3-adamantan-1-ylureido)dodecanoic acid	50-94	epoxide hydrolase 2	Homo sapiens	132-135
20008283-2	2010	Tension measurements performed in the presence of 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), a soluble epoxide hydrolase (sEH)-specific inhibitor, demonstrated that 17,18-EpETE reduced the reactivity of TNF-alpha-pretreated tissues.	12-(3-adamantan-1-ylureido)dodecanoic acid	50-94	tumor necrosis factor	Homo sapiens	213-222
20008283-2	2010	Tension measurements performed in the presence of 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), a soluble epoxide hydrolase (sEH)-specific inhibitor, demonstrated that 17,18-EpETE reduced the reactivity of TNF-alpha-pretreated tissues.	12-(3-adamantan-1-ylureido)dodecanoic acid	96-100	epoxide hydrolase 2	Homo sapiens	105-130
20008283-7	2010	The presence of SB203580, a p38-MAPK inhibitor, reversed the effect induced by epoxy-eicosanoid in the presence of AUDA on TNF-alpha-triggered Ca(2+) hypersensitivity by increasing the phosphorylation level of PKC Potentiated Inhibitor Protein-17 (CPI-17) regulatory protein.	12-(3-adamantan-1-ylureido)dodecanoic acid	115-119	mitogen-activated protein kinase 14	Homo sapiens	28-36
20008283-7	2010	The presence of SB203580, a p38-MAPK inhibitor, reversed the effect induced by epoxy-eicosanoid in the presence of AUDA on TNF-alpha-triggered Ca(2+) hypersensitivity by increasing the phosphorylation level of PKC Potentiated Inhibitor Protein-17 (CPI-17) regulatory protein.	12-(3-adamantan-1-ylureido)dodecanoic acid	115-119	tumor necrosis factor	Homo sapiens	123-132
20008283-7	2010	The presence of SB203580, a p38-MAPK inhibitor, reversed the effect induced by epoxy-eicosanoid in the presence of AUDA on TNF-alpha-triggered Ca(2+) hypersensitivity by increasing the phosphorylation level of PKC Potentiated Inhibitor Protein-17 (CPI-17) regulatory protein.	12-(3-adamantan-1-ylureido)dodecanoic acid	115-119	protein phosphatase 1 regulatory inhibitor subunit 14A	Homo sapiens	248-254
20035028-4	2010	We demonstrated that chronic treatment of spontaneously hypertensive stroke-prone rats with 12-(3-adamantan-1-yl-ureido) dodecanoic acid, an inhibitor of SEH, improved the increment of inward remodeling induced by common carotid ligation to a level that was comparable with normotensive Wistar Kyoto rats.	12-(3-adamantan-1-ylureido)dodecanoic acid	92-136	epoxide hydrolase 2	Rattus norvegicus	154-157
19435785-3	2009	Here we show that 6 weeks of SEH inhibition via 2 mg/day of 12-(3-adamantan-1-yl-ureido) dodecanoic acid (AUDA) in spontaneously hypertensive stroke-prone (SHRSP) rats protects against cerebral ischemia induced by middle cerebral artery occlusion, reducing percent hemispheric infarct and neurodeficit score without decreasing blood pressure.	12-(3-adamantan-1-ylureido)dodecanoic acid	60-104	epoxide hydrolase 2	Rattus norvegicus	29-32
19435785-3	2009	Here we show that 6 weeks of SEH inhibition via 2 mg/day of 12-(3-adamantan-1-yl-ureido) dodecanoic acid (AUDA) in spontaneously hypertensive stroke-prone (SHRSP) rats protects against cerebral ischemia induced by middle cerebral artery occlusion, reducing percent hemispheric infarct and neurodeficit score without decreasing blood pressure.	12-(3-adamantan-1-ylureido)dodecanoic acid	106-110	epoxide hydrolase 2	Rattus norvegicus	29-32
18459944-3	2009	We hypothesized that the sEH inhibitor AUDA [12-(3-adamantan-1-yl-ureido)-dodecanoic acid] protects the kidney from the development of nephropathy associated with hypertension and Type 2 diabetes.	12-(3-adamantan-1-ylureido)dodecanoic acid	39-43	epoxide hydrolase 2	Rattus norvegicus	25-28
19226702-3	2009	METHODS: sEH inhibition was achieved using 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (25 mg/l) and cis- 4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid (5 mg/l) administered via drinking water starting 3 days prior to monocrotaline injection (60 mg/kg).	12-(3-adamantan-1-ylureido)dodecanoic acid	43-87	epoxide hydrolase 2	Rattus norvegicus	9-12
18459944-3	2009	We hypothesized that the sEH inhibitor AUDA [12-(3-adamantan-1-yl-ureido)-dodecanoic acid] protects the kidney from the development of nephropathy associated with hypertension and Type 2 diabetes.	12-(3-adamantan-1-ylureido)dodecanoic acid	45-89	epoxide hydrolase 2	Rattus norvegicus	25-28
18459944-11	2009	Taken together, these results provide evidence that sEH inhibition with AUDA attenuates the progression of renal damage associated with hypertension and Type 2 diabetes.	12-(3-adamantan-1-ylureido)dodecanoic acid	72-76	epoxide hydrolase 2	Rattus norvegicus	52-55
18508449-0	2008	Soluble epoxide hydrolase inhibitor, AUDA, prevents early salt-sensitive hypertension.	12-(3-adamantan-1-ylureido)dodecanoic acid	37-41	epoxide hydrolase 2	Rattus norvegicus	0-25
18815352-4	2008	Continuous dosing of the sEH inhibitors 12-(3-adamantan-1-ylureido)-dodecanoic acid (AUDA), a polyethylene glycol ester of AUDA, and 1-adamantan-1-yl-3-(5-(2-(2-ethoxyethoxy)ethoxy)-pentyl)urea resulted in robust exposure to the inhibitor and target engagement, as evidenced by significant increases in plasma EET/DHET ratios following 6 days of inhibitor treatment.	12-(3-adamantan-1-ylureido)dodecanoic acid	40-83	epoxide hydrolase 2, cytoplasmic	Mus musculus	25-28
18815352-4	2008	Continuous dosing of the sEH inhibitors 12-(3-adamantan-1-ylureido)-dodecanoic acid (AUDA), a polyethylene glycol ester of AUDA, and 1-adamantan-1-yl-3-(5-(2-(2-ethoxyethoxy)ethoxy)-pentyl)urea resulted in robust exposure to the inhibitor and target engagement, as evidenced by significant increases in plasma EET/DHET ratios following 6 days of inhibitor treatment.	12-(3-adamantan-1-ylureido)dodecanoic acid	85-89	epoxide hydrolase 2, cytoplasmic	Mus musculus	25-28
18815352-4	2008	Continuous dosing of the sEH inhibitors 12-(3-adamantan-1-ylureido)-dodecanoic acid (AUDA), a polyethylene glycol ester of AUDA, and 1-adamantan-1-yl-3-(5-(2-(2-ethoxyethoxy)ethoxy)-pentyl)urea resulted in robust exposure to the inhibitor and target engagement, as evidenced by significant increases in plasma EET/DHET ratios following 6 days of inhibitor treatment.	12-(3-adamantan-1-ylureido)dodecanoic acid	123-127	epoxide hydrolase 2, cytoplasmic	Mus musculus	25-28
18508449-2	2008	Since epoxyeicosatrienoic acids (EETs) possess vasodepressor and natriuretic activities, we examined whether a soluble epoxide hydrolase (sEH) inhibitor, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), to inhibit the metabolism of EETs, would protect against pathologic changes in SHRSP.	12-(3-adamantan-1-ylureido)dodecanoic acid	154-198	epoxide hydrolase 2	Rattus norvegicus	111-136
18508449-2	2008	Since epoxyeicosatrienoic acids (EETs) possess vasodepressor and natriuretic activities, we examined whether a soluble epoxide hydrolase (sEH) inhibitor, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), to inhibit the metabolism of EETs, would protect against pathologic changes in SHRSP.	12-(3-adamantan-1-ylureido)dodecanoic acid	154-198	epoxide hydrolase 2	Rattus norvegicus	138-141
16772540-6	2006	Mesenteric arteries were then incubated with increasing concentrations of the sEH inhibitor 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA).	12-(3-adamantan-1-ylureido)dodecanoic acid	92-135	epoxide hydrolase 2	Rattus norvegicus	78-81
17046265-0	2007	Design of bioavailable derivatives of 12-(3-adamantan-1-yl-ureido)dodecanoic acid, a potent inhibitor of the soluble epoxide hydrolase.	12-(3-adamantan-1-ylureido)dodecanoic acid	38-81	epoxide hydrolase 2	Homo sapiens	109-134
17046265-2	2007	12-(3-Adamantan-1-yl-ureido)-dodecanoic acid (AUDA, 1) is a very active inhibitor of sEH both in vitro and in vivo.	12-(3-adamantan-1-ylureido)dodecanoic acid	0-44	epoxide hydrolase 2	Homo sapiens	85-88
17046265-2	2007	12-(3-Adamantan-1-yl-ureido)-dodecanoic acid (AUDA, 1) is a very active inhibitor of sEH both in vitro and in vivo.	12-(3-adamantan-1-ylureido)dodecanoic acid	46-50	epoxide hydrolase 2	Homo sapiens	85-88
16267130-4	2005	In the presence of adamantyl-ureido-dodecanoic acid (AUDA), a soluble epoxide hydrolase (sEH)-specific inhibitor, EETs increased PPARgamma transcription activity in endothelial cells and 3T3-L1 preadipocytes.	12-(3-adamantan-1-ylureido)dodecanoic acid	53-57	epoxide hydrolase 2	Homo sapiens	62-87
16306811-3	2005	We hypothesized that 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), a sEH inhibitor, would protect stroke-prone spontaneously hypertensive rats from cerebral ischemia.	12-(3-adamantan-1-ylureido)dodecanoic acid	21-64	epoxide hydrolase 2	Rattus norvegicus	75-78
16306811-3	2005	We hypothesized that 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), a sEH inhibitor, would protect stroke-prone spontaneously hypertensive rats from cerebral ischemia.	12-(3-adamantan-1-ylureido)dodecanoic acid	66-70	epoxide hydrolase 2	Rattus norvegicus	75-78
16267130-4	2005	In the presence of adamantyl-ureido-dodecanoic acid (AUDA), a soluble epoxide hydrolase (sEH)-specific inhibitor, EETs increased PPARgamma transcription activity in endothelial cells and 3T3-L1 preadipocytes.	12-(3-adamantan-1-ylureido)dodecanoic acid	53-57	epoxide hydrolase 2	Homo sapiens	89-92
16267130-4	2005	In the presence of adamantyl-ureido-dodecanoic acid (AUDA), a soluble epoxide hydrolase (sEH)-specific inhibitor, EETs increased PPARgamma transcription activity in endothelial cells and 3T3-L1 preadipocytes.	12-(3-adamantan-1-ylureido)dodecanoic acid	53-57	peroxisome proliferator activated receptor gamma	Homo sapiens	129-138
34464816-6	2021	Moreover, compounds 20, 22, and 29 were the most potent dual COX-2/sEH inhibitors, with IC50 values of 0.95, 0.80, and 0.85 nM against sEH, respectively, and were more potent than the standard AUDA (IC50 = 1.2 nM).	12-(3-adamantan-1-ylureido)dodecanoic acid	193-197	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	61-66
16157792-3	2005	The sEH inhibitor, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), was given orally to angiotensin-infused animals during the 14-day period.	12-(3-adamantan-1-ylureido)dodecanoic acid	19-63	epoxide hydrolase 2	Rattus norvegicus	4-7
16157792-3	2005	The sEH inhibitor, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), was given orally to angiotensin-infused animals during the 14-day period.	12-(3-adamantan-1-ylureido)dodecanoic acid	65-69	epoxide hydrolase 2	Rattus norvegicus	4-7
15798002-6	2005	CUDA and AUDA were metabolized to chain-shortened beta-oxidation products, a process that reduced their potency as sEH inhibitors and their ability to bind and activate PPARalpha.	12-(3-adamantan-1-ylureido)dodecanoic acid	9-13	epoxide hydrolase 2	Homo sapiens	115-118
15798002-6	2005	CUDA and AUDA were metabolized to chain-shortened beta-oxidation products, a process that reduced their potency as sEH inhibitors and their ability to bind and activate PPARalpha.	12-(3-adamantan-1-ylureido)dodecanoic acid	9-13	peroxisome proliferator activated receptor alpha	Homo sapiens	169-178
15798002-9	2005	We conclude that CUDA and AUDA, by virtue of their carboxylic acid substitution, activate PPARalpha in addition to potently inhibiting sEH.	12-(3-adamantan-1-ylureido)dodecanoic acid	26-30	peroxisome proliferator activated receptor alpha	Homo sapiens	90-99
15798002-9	2005	We conclude that CUDA and AUDA, by virtue of their carboxylic acid substitution, activate PPARalpha in addition to potently inhibiting sEH.	12-(3-adamantan-1-ylureido)dodecanoic acid	26-30	epoxide hydrolase 2	Homo sapiens	135-138
34464816-6	2021	Moreover, compounds 20, 22, and 29 were the most potent dual COX-2/sEH inhibitors, with IC50 values of 0.95, 0.80, and 0.85 nM against sEH, respectively, and were more potent than the standard AUDA (IC50 = 1.2 nM).	12-(3-adamantan-1-ylureido)dodecanoic acid	193-197	epoxide hydrolase 2	Homo sapiens	67-70
34149359-2	2021	Reportedly, the main effect of AUDA is exerting anti-inflammation and neovascularization via the inhibition of soluble epoxide hydrolase.	12-(3-adamantan-1-ylureido)dodecanoic acid	31-35	epoxide hydrolase 2	Rattus norvegicus	111-136
35378826-2	2022	Methods: Leptin receptor-deficient (db/db) mice were treated with either the soluble epoxide hydrolase (sEH) inhibitor AUDA or vehicle alone.	12-(3-adamantan-1-ylureido)dodecanoic acid	119-123	leptin receptor	Mus musculus	9-24
35378826-2	2022	Methods: Leptin receptor-deficient (db/db) mice were treated with either the soluble epoxide hydrolase (sEH) inhibitor AUDA or vehicle alone.	12-(3-adamantan-1-ylureido)dodecanoic acid	119-123	epoxide hydrolase 2, cytoplasmic	Mus musculus	77-102
35378826-2	2022	Methods: Leptin receptor-deficient (db/db) mice were treated with either the soluble epoxide hydrolase (sEH) inhibitor AUDA or vehicle alone.	12-(3-adamantan-1-ylureido)dodecanoic acid	119-123	epoxide hydrolase 2, cytoplasmic	Mus musculus	104-107
35378826-7	2022	Results: The sEH inhibitor AUDA significantly attenuated ventricular remodeling and ameliorated cardiac dysfunction in db/db mice.	12-(3-adamantan-1-ylureido)dodecanoic acid	27-31	epoxide hydrolase 2, cytoplasmic	Mus musculus	13-16
35378826-11	2022	However, AUDA-induced autophagy was abolished, and the antiapoptotic effect was partially inhibited upon Nrf2 knockdown.	12-(3-adamantan-1-ylureido)dodecanoic acid	9-13	nuclear factor, erythroid derived 2, like 2	Mus musculus	105-109
35378826-12	2022	Conclusion: Our findings suggest that the sEH inhibitor AUDA attenuates cardiac remodeling and dysfunction in DCM via increasing autophagy and reducing apoptosis, which is relevant to activate Nrf2 signaling pathway.	12-(3-adamantan-1-ylureido)dodecanoic acid	56-60	epoxide hydrolase 2, cytoplasmic	Mus musculus	42-45
35378826-12	2022	Conclusion: Our findings suggest that the sEH inhibitor AUDA attenuates cardiac remodeling and dysfunction in DCM via increasing autophagy and reducing apoptosis, which is relevant to activate Nrf2 signaling pathway.	12-(3-adamantan-1-ylureido)dodecanoic acid	56-60	nuclear factor, erythroid derived 2, like 2	Mus musculus	193-197
34336035-13	2021	In addition, the anti-apoptotic effect of si-Ephx2 was enhanced in the presence of AUDA-pharmacological Ephx2 inhibitor.	12-(3-adamantan-1-ylureido)dodecanoic acid	83-87	epoxide hydrolase 2	Rattus norvegicus	45-50
34336035-13	2021	In addition, the anti-apoptotic effect of si-Ephx2 was enhanced in the presence of AUDA-pharmacological Ephx2 inhibitor.	12-(3-adamantan-1-ylureido)dodecanoic acid	83-87	epoxide hydrolase 2	Rattus norvegicus	104-109